Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Nov;32(11):1636-1640.
doi: 10.1002/mds.27127. Epub 2017 Sep 14.

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study

Affiliations
Observational Study

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study

Michelle E Fullard et al. Mov Disord. 2017 Nov.

Abstract

Background: Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD.

Objectives: To evaluate vitamin D levels in a population at risk for developing PD.

Methods: Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity.

Results: Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake.

Conclusions: Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin D insufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis. © 2017 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; cognition; cohort studies; vitamin D.

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

Figures

FIG. 1
FIG. 1
Vitamin D levels and status in PARS participants stratified by risk. (A) Swarm plots with box plots of vitamin D levels in the high-risk group (hyposmia + DAT<80%) vs. all others. (B) Swarm plots with box plots of vitamin D levels in the highest-risk group (hyposmia + DAT <65%) vs. all others. (C) Vitamin D deficiency and insufficiency in the high-risk group (hyposmia + DAT <80%) vs. all others. (D) Vitamin D deficiency and insufficiency in the highest-risk group (hyposmia + DAT <65%) vs. all others. Box plots denote median and interquartile range. Vitamin D deficiency is defined as total vitamin D <20 ng/mL, insufficiency as total vitamin D 20 to 30 ng/mL, and sufficiency as total vitamin D >30 ng/mL.

References

    1. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–1352. - PMC - PubMed
    1. Lee YH, Kim JH, Song GG. Vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease and Alzheimer’s disease: a meta-analysis. Neurol Sci. 2014;35:1947–1953. - PubMed
    1. Ding H, Dhima K, Lockhart KC, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81:1531–1537. - PMC - PubMed
    1. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007;68:911–915. - PubMed
    1. Zhao Y, Sun Y, Ji HF, Shen L. Vitamin D levels in Alzheimer’s and Parkinson’s diseases: a meta-analysis. Nutrition. 2013;29:828–832. - PubMed

Publication types

Substances